viral
infect
probabl
caus
respiratori
tract
diseas
nonetheless
estim
million
million
antibiot
prescript
respiratori
tract
infect
includ
lower
upper
respiratori
infect
caus
unlik
bacteri
etiolog
although
mani
case
otiti
sinus
probabl
case
communityacquir
pneumonia
bacteri
superinfect
may
occur
respiratori
infect
due
viru
es
alon
common
adult
pediatr
outpati
popul
addit
vast
major
respiratori
tract
infect
nonimmunocompromis
hospit
children
especi
year
age
due
virus
without
secondari
bacteri
infect
overus
antibiot
treatment
outpati
primarili
due
fact
adult
respiratori
viru
test
either
perform
gener
limit
rapid
antigen
direct
test
radt
influenza
test
elderli
person
chronic
obstruct
pulmonari
diseas
pediatr
patient
limit
radt
influenza
respiratori
syncyti
viru
rsv
radt
highli
variabl
sensit
specif
depend
viral
target
age
patient
sampl
collect
durat
symptom
prior
test
gener
radt
perform
better
test
pediatr
sampl
children
shed
higher
titer
viru
longer
time
period
adult
addit
radt
us
food
drug
administr
fda
approvedclear
nonmolecularbas
viral
diagnost
method
rapid
time
result
compar
tradit
viral
tube
cultur
eg
direct
fluoresc
antibodi
dfa
test
rapid
cell
cultur
method
readili
detect
common
respiratori
virus
adenoviru
influenza
influenza
b
parainfluenza
rsv
addit
dfa
test
detect
human
metapneumoviru
hmpv
specif
dfa
test
rapid
cell
cultur
high
sensit
test
vari
low
rsv
cultur
high
influenza
compar
nucleic
acid
amplif
test
naat
dfa
test
perform
littl
min
shell
vial
rmix
rapid
cell
cultur
quideldiagnost
hybrid
gener
identifi
respiratori
virus
h
test
perform
site
time
viru
detect
within
time
frame
could
affect
patient
manag
howev
test
wide
avail
outsid
larger
hospit
refer
laboratori
although
virus
respons
larg
number
respiratori
tract
infect
bocaviru
select
coronavirus
parainfluenza
rhinoviru
also
import
caus
respiratori
diseas
gener
detect
use
naat
antivir
therapi
current
limit
treatment
influenza
influenza
b
cytomegaloviru
pneumonia
varicella
zoster
viru
pneumonia
often
argu
specif
identif
virus
relev
inform
would
chang
patient
manag
treatment
standpoint
may
current
true
howev
respiratori
virus
caus
similar
ill
diagnosi
base
clinic
symptom
alon
highli
inaccur
exampl
studi
poehl
et
al
reveal
physician
use
clinic
symptom
recogn
influenza
hospit
children
nonhospit
children
laboratoryconfirm
influenza
therefor
establish
viral
etiolog
characterist
ill
often
highli
depend
accur
diagnost
test
addit
new
therapeut
agent
respiratori
virus
develop
clinic
trial
agent
need
rapid
diagnost
detect
broad
rang
viral
pathogen
new
drug
approv
clinic
laboratori
need
tool
identifi
viru
appropri
antivir
therapi
rapidli
initi
addit
first
week
influenza
outbreak
spring
multipl
influenza
virus
cocircul
necessari
subtyp
influenza
strain
differenti
season
influenza
season
influenza
influenza
subtyp
necessari
provid
relev
inform
need
appropri
select
antivir
therapi
particular
acut
ill
patient
antivir
resist
test
influenza
isol
wwwcdcgovflu
reveal
circul
season
influenza
strain
resist
oseltamivir
season
influenza
influenza
resist
adamantan
addit
sever
patient
influenza
infect
develop
oseltamivir
resist
clinic
factor
potenti
develop
sever
diseas
basi
viru
etiolog
may
need
consid
manag
certain
patient
exampl
studi
laboratori
reveal
children
hmpv
infect
higher
incid
admiss
intens
care
unit
often
requir
mechan
ventil
children
rsv
infect
especi
treatment
inpati
cost
rapid
viral
diagnost
offset
improv
patient
care
financi
outcom
hendrickson
et
al
show
rapid
respiratori
viru
diagnosi
lead
benefit
sever
area
includ
reduct
hospit
day
reduct
antibiot
use
reduct
unnecessari
diagnost
test
procedur
burden
nosocomi
influenza
high
incur
addit
cost
diagnost
test
increas
morbid
extend
hospit
therefor
rapid
diagnost
test
need
identifi
patient
influenza
admiss
order
prevent
nosocomi
transmiss
facilit
isol
cohort
decis
studi
document
substanti
nosocomi
transmiss
hmpv
pediatr
unit
well
chronic
care
facil
similar
seen
rsv
height
rsv
season
mani
institut
must
cohort
rsvposit
children
lack
privat
room
howev
dual
infect
rsv
hmpv
occur
limit
diagnost
rsv
alon
cohort
scenario
could
put
serious
ill
children
risk
acquisit
second
viral
infect
hmpv
mean
mix
viral
infect
defin
test
comprehens
broad
test
panel
also
allow
monitor
epidemiolog
pattern
respiratori
diseas
identifi
new
reemerg
pathogen
final
identif
exact
respiratori
viru
essenti
accur
assess
efficaci
vaccin
cost
test
use
fdaapprovedclear
naat
highli
variabl
rang
approxim
per
test
factor
determin
test
cost
includ
test
volum
price
test
kit
number
test
per
kit
size
test
run
number
control
requir
per
test
run
type
amount
ancillari
suppli
often
fdaapprovedclear
kit
contain
nucleic
acid
extract
reagent
addit
equip
reagent
necessari
add
per
test
batch
test
sampl
may
reduc
cost
per
test
howev
often
batch
practic
time
result
delay
beyond
period
would
affect
either
clinic
manag
infect
control
practic
instrument
cost
molecular
test
substanti
realtim
instrument
cost
averag
per
instrument
higher
volum
laboratori
may
requir
multipl
instrument
laboratori
must
also
calcul
cost
technic
time
highli
variabl
depend
test
complex
run
size
final
cost
qualiti
control
profici
test
compet
assess
affect
overal
cost
per
test
decid
test
appropri
cost
patient
popul
particular
health
care
facil
factor
need
consid
light
clinic
impact
test
result
use
naat
intrins
part
infecti
diseas
diagnost
abil
naat
rapidli
accur
detect
novel
pathogen
best
exemplifi
influenza
pandem
naat
especi
suit
identif
respiratori
pathogen
routin
easili
cultur
eg
hmpv
bocaviru
parainfluenza
chlamydophila
pneumonia
pathogen
danger
cultur
eg
sever
acut
respiratori
syndrom
coronaviru
pathogen
time
detect
tradit
mean
often
delay
affect
patient
care
eg
tube
cell
cultur
influenza
pathogen
serolog
test
difficult
interpret
eg
c
pneumonia
case
naat
offer
enhanc
sensit
cultur
method
radt
dfa
test
specif
naat
vari
target
assay
design
gener
high
addit
laboratorydevelop
naat
valid
accord
clinic
laboratori
improv
amend
clia
requir
use
identifi
new
pathogen
fdaapprovedclear
vitro
diagnost
ivd
devic
becom
avail
clinic
integr
realtim
polymeras
chain
reaction
pcr
fdaapprovedclear
simpl
naat
laboratori
size
abl
perform
molecular
diagnost
test
amtd
targetamplifi
nucleic
acid
probe
test
direct
detect
tuberculosi
complex
mycobacterium
bovi
bovi
bcg
mycobacterium
africanum
mycobacterium
microti
tuberculosi
ribosom
rna
rrna
amtd
approv
test
afb
smearneg
respiratori
specimen
collect
patient
suspect
tuberculosi
colon
infect
amtd
test
base
isotherm
transcriptionmedi
amplif
use
enzym
revers
transcriptas
rt
rna
polymeras
targetspecif
primer
hybrid
protect
detect
assay
use
chemiluminescentlabel
singlestrand
dna
probe
complementari
tuberculosi
sequenc
detect
amplifi
rrna
use
genprob
leader
luminomet
numer
studi
evalu
amtd
reveal
averag
sensit
specif
respect
detect
tuberculosi
complex
smearposit
respiratori
sampl
sensit
specif
respect
smearneg
respiratori
sampl
addit
studi
evalu
use
test
sever
type
nonrespiratori
sampl
cerebrospin
fluid
lymph
node
amplicor
mycobacterium
tuberculosi
test
fda
approv
use
afb
respiratori
specimen
patient
suspect
tuberculosi
infect
colon
amplicor
mycobacterium
tuberculosi
test
use
tradit
pcr
amplifi
region
gene
encod
rrna
mycobacteria
member
tuberculosi
complex
identifi
hybrid
dna
probe
follow
substrat
addit
colorimetr
detect
test
afb
sampl
amplicor
mycobacterium
tuberculosi
test
demonstr
sensit
specif
detect
tuberculosi
complex
rang
respect
sensit
specif
amplicor
mycobacterium
tuberculosi
afb
specimen
rang
respect
amplicor
mycobacterium
tuberculosi
test
also
evalu
detect
tuberculosi
mening
use
nonrespiratori
sampl
type
first
multiplex
naat
receiv
clearanc
fda
xtag
respiratori
viru
panel
rvp
assay
januari
fdaapprov
version
rvp
detect
adenoviru
influenza
subtyp
season
influenza
season
influenza
influenza
b
hmpv
rhinoviru
rsv
rsv
b
uscanadian
research
version
assay
also
detect
coronavirus
parainfluenza
type
enteroviru
test
approv
use
nasopharyng
swab
sampl
collect
person
symptomat
respiratori
viru
infect
place
viral
transport
media
xtag
rvp
multistep
test
take
approxim
h
complet
depend
number
sampl
test
figur
viral
nucleic
acid
intern
control
e
coli
phage
coextract
clinic
sampl
use
qiaamp
minielut
qiagen
easymag
minimag
extract
platform
multiplex
revers
transcript
polymeras
chain
reaction
rtpcr
use
primer
set
specif
test
target
amplifi
viral
nucleic
acid
intern
control
nucleic
acid
pcr
product
treat
exonucleas
degrad
remain
primer
shrimp
alkalin
phosphatas
degrad
remain
nucleotid
next
step
consist
targetspecif
primer
extens
tspe
viral
target
present
targetspecif
primer
contain
uniqu
tag
sequenc
extend
triphosph
incorpor
extend
chain
complet
tspe
detect
amplifi
product
perform
use
luminex
univers
tag
sort
system
tspe
reaction
ad
directli
microwel
contain
spectral
distinguish
bead
antitag
complementari
sequenc
tag
primer
tag
primer
hybrid
uniqu
antitag
complement
associ
specif
color
bead
fluoresc
report
molecul
streptavidinphycoerythrin
bind
biotin
extend
primer
bead
analyz
luminex
xmap
instrument
two
laser
read
bead
first
identifi
virusspecif
colorcod
bead
second
determin
whether
amplicon
hybrid
bead
basi
detect
fluoresc
mean
fluoresc
intens
mfi
background
threshold
clinic
perform
characterist
xtag
rvp
assay
establish
manufactur
prospect
collect
nasopharyng
swab
sampl
n
test
influenza
season
north
american
clinic
laboratori
specimen
test
mean
viral
cultur
andor
dfa
test
follow
target
influenza
influenza
b
rsv
adenoviru
compar
method
influenza
subtyp
rsv
subtyp
hmpv
rhinoviru
detect
wellcharacter
rtpcr
assay
follow
bidirect
sequenc
xtag
rvp
sensit
target
determin
follow
influenza
influenza
subtyp
influenza
subtyp
influenza
b
rsv
rsv
b
adenoviru
rhinoviru
hmpv
xtag
rvp
specif
target
determin
follow
influenza
influenza
subtyp
influenza
subtyp
influenza
b
rsv
rsv
b
adenoviru
rhinoviru
hmpv
studi
mahoney
et
al
use
research
version
xtag
rvp
assay
nasopharyng
swab
specimen
compar
xtag
rvp
combin
dfa
test
viral
cultur
virus
grown
cultur
overal
sensit
specif
dfa
testingcultur
respect
compar
respect
xtag
rvp
virus
routin
cultur
also
includ
evalu
sensit
dfa
testingcultur
compar
xtag
rvp
addit
specimen
contain
viru
wong
et
al
found
highli
multiplex
xtag
rvp
assay
enhanc
laboratori
investig
respiratori
viru
outbreak
aid
heath
care
facil
patient
outbreak
manag
studi
evalu
perform
xtag
rvp
influenza
outbreak
area
new
york
new
york
demonstr
sensit
xtag
rvp
detect
influenza
compar
rmix
cultur
dfa
test
radt
xtag
rvp
detect
respiratori
viru
sampl
influenza
numer
mix
viral
infect
also
identifi
ginocchio
st
georg
determin
probabl
influenza
infect
due
unsubtyp
strain
season
influenza
season
influenza
accord
xtag
rvp
assay
identifi
outbreak
identif
influenza
basi
studi
fda
approv
chang
packag
insert
state
xtag
rvp
effect
aid
detect
influenza
specif
identifi
influenza
hemagglutinin
gene
benefit
xtag
rvp
assay
includ
broad
spectrum
virus
detect
singl
test
cost
per
test
compar
realtim
assay
target
analyt
subtyp
influenza
virus
season
influenza
season
influenza
identif
unsubtyp
viru
proven
import
aid
identifi
novel
influenza
strain
limit
assay
decreas
sensit
detect
certain
adenoviru
strain
inhous
valid
studi
laboratori
found
reduc
posit
cutoff
mfi
level
adenoviru
improv
sensit
detect
adenoviru
obtain
without
loss
specif
unpublish
data
addit
limit
assay
includ
time
final
result
number
requir
step
technic
handson
time
potenti
amplicon
contamin
secondgener
assay
call
rvp
fast
luminex
avail
europ
address
sever
issu
reduc
number
step
time
result
h
make
possibl
provid
comprehens
result
within
singl
shift
current
genprobeprodess
fdaclear
multiplex
realtim
rtpcr
assay
qualit
detect
discrimin
respiratori
virus
proflu
assay
target
matrix
gene
influenza
nonstructur
gene
influenza
b
polymeras
gene
rsv
rsv
b
pro
hmpv
assay
target
highli
conserv
region
nucleocapsid
n
gene
hmpv
transcript
deriv
escherichia
coli
bacteriophag
aprotein
gene
intern
control
proparaflu
assay
target
conserv
region
hemagglutininneuraminidas
gene
transcript
deriv
e
coli
bacteriophag
aprotein
gene
intern
control
assay
approv
test
nasopharyng
swab
specimen
obtain
symptomat
person
viral
nucleic
acid
patient
sampl
coextract
intern
control
monitor
assay
perform
presenc
amplif
inhibitor
could
lead
falseneg
result
nucleic
acid
extract
use
magna
pure
lc
instrument
roch
diagnost
corp
magna
pure
total
nucleic
acid
isol
kit
roch
nuclisen
easymag
system
autom
magnet
extract
reagent
purifi
nucleic
acid
amplifi
mean
rtpcr
use
targetspecif
oligonucleotid
primer
taqman
probe
complementari
highli
conserv
region
target
gene
taqman
probe
label
quencher
dye
attach
report
dye
amplifi
target
present
probe
bind
exonucleas
activ
taq
polymeras
cleav
probe
thu
separ
report
dye
quencher
quencher
report
dye
physic
separ
increas
fluoresc
signal
upon
excit
light
sourc
fluoresc
signal
increas
cycl
addit
report
dye
molecul
cleav
respect
probe
pcr
cycl
fluoresc
intens
monitor
realtim
instrument
smartcycl
ii
time
result
includ
extract
approxim
hr
test
run
perform
characterist
assay
establish
manufactur
prospect
retrospect
clinic
studi
use
fda
clearanc
test
proflu
assay
result
obtain
test
nasopharyng
sampl
compar
result
rapid
shell
vial
cultur
proflu
sensit
specif
detect
influenza
respect
influenza
b
respect
rsv
respect
studi
liao
et
al
compar
prodess
assay
previou
version
proflu
assay
viral
cultur
radt
rsv
rsv
binax
inver
medic
influenza
b
directogen
ab
bd
diagnost
specif
method
found
sensit
detect
influenza
directogen
b
viral
cultur
sensit
detect
rsv
rsv
viral
cultur
anoth
studi
legoff
et
al
evalu
perform
pediatr
nasopharyng
specimen
result
compar
dfa
test
viral
cultur
sensit
specif
rang
detect
virus
sampl
neg
result
convent
method
respons
influenza
outbreak
influenza
subtyp
assay
proflust
develop
prodess
receiv
emerg
use
author
eua
fda
juli
see
eua
section
proflust
qualit
multiplex
realtim
rtpcr
assay
target
nucleoprotein
gene
influenza
specif
hemagglutinin
gene
season
influenza
season
influenza
intern
control
phage
identif
influenza
aid
algorithm
reli
season
influenza
viru
season
influenza
viru
result
nasopharyng
swab
specimen
patient
receiv
diagnosi
influenza
current
avail
fdaclear
author
devic
assay
intend
use
clia
highcomplex
laboratori
perform
assay
evalu
retrospect
use
nasopharyng
swab
specimen
previous
test
either
cdc
rrtpcr
flu
panel
ivd
devic
detect
season
influenza
influenza
cdc
rrtpcr
swine
flu
panel
eua
posit
neg
agreement
detect
season
influenza
respect
season
influenza
respect
influenza
respect
pro
hmpv
assay
clinic
trial
studi
fda
clearanc
evalu
assay
clinic
perform
use
nasopharyng
swab
specimen
test
clinic
laboratori
across
unit
state
use
luminex
rvp
assay
predic
devic
sensit
pro
hmpv
specif
perform
proparaflu
assay
evalu
clinic
trial
fda
clearanc
use
nasopharyng
swab
specimen
test
clinic
laboratori
across
unit
state
sensit
specif
assay
detect
respect
detect
respect
detect
respect
time
addit
independ
perform
data
avail
benefit
genprobeprodess
assay
includ
eas
use
approxim
h
handson
time
nucleic
acid
extract
prepar
rtpcr
setup
overal
time
result
h
multipl
smartcycl
instrument
run
simultan
mani
unit
per
cycler
use
need
give
flexibl
run
size
tube
contain
amplicon
never
open
risk
amplicon
contamin
minim
one
limit
assay
maximum
target
plu
intern
control
detect
singl
reaction
therefor
comprehens
viral
diagnost
panel
requir
multipl
pcr
multipl
pcr
costli
laboratori
technic
time
reagent
cost
howev
limit
panel
size
could
provid
mixandmatch
test
menu
allow
clinician
option
select
sever
panel
firstgener
verigen
respiratori
viru
nucleic
acid
test
vrnat
clear
fda
may
test
replac
autom
verigen
vrnatsp
clia
moder
complex
test
intend
identif
influenza
influenza
b
rsv
type
b
inclus
nasopharyng
swab
specimen
place
viral
transport
media
verigen
system
consist
instrument
fulli
autom
verigen
processor
verigen
reader
singleus
test
cartridg
figur
entir
test
process
requir
user
pipet
step
less
min
technic
handson
time
sampletoresult
turnaround
time
h
basi
vrnatsp
nanospher
proprietari
gold
nanoparticl
hybrid
technolog
gold
nanoparticl
contain
high
densiti
sequencespecif
oligonucleotid
high
affin
complementari
dna
allow
effici
hybrid
kinet
clinic
sampl
pipet
singleus
extract
tray
load
verigen
process
unit
chaotrop
agent
ad
sampl
lyse
cell
viral
particl
intern
control
phage
ad
prior
extract
step
releas
nucleic
acid
captur
magnet
microparticl
mmp
mmpbound
nucleic
acid
wash
purifi
nucleic
acid
elut
mmp
transfer
amplif
tray
rtpcr
perform
use
primer
target
influenza
matrix
gene
influenza
b
matrix
gene
nonstructur
gene
rsv
l
gene
f
gene
rtpcr
reaction
follow
primari
hybrid
step
primari
hybrid
target
dna
simultan
hybrid
targetspecif
captur
dna
oligonucleotid
array
replic
solid
substrat
microarray
targetspecif
mediat
dna
oligonucleotid
remov
uncaptur
target
nucleic
acid
unhybrid
mediat
oligonucleotid
process
continu
secondari
hybrid
microarray
spot
appropri
target
hybrid
captur
oligonucleotid
mediat
oligonucleotid
satur
silverco
gold
nanoparticl
probe
hybrid
cartridg
remov
processor
unit
glass
slide
microarray
separ
cartridg
insert
verigen
reader
lightscatt
techniqu
slide
illumin
intern
light
parallel
slide
surfac
use
analyz
result
spot
silverenhanc
gold
nanoparticl
probe
present
scatter
light
light
scatter
detect
optic
translat
measur
signal
perform
characterist
firstgener
vrnat
assay
establish
clinic
trial
ivd
devic
clearanc
vrnat
compar
viral
culturedfa
test
bidirect
sequenc
resolv
discord
result
test
sensit
specif
detect
influenza
respect
influenza
b
respect
rsv
respect
comparison
vrnat
vrnatsp
reveal
overal
posit
agreement
neg
agreement
valu
benefit
vrnatsp
system
includ
scalabl
system
addit
multipl
processor
reader
individu
sampl
process
random
access
format
minim
handson
time
minim
technic
expertis
requir
perform
test
test
clia
moder
complex
train
laboratori
technician
could
perform
test
test
would
well
suit
small
mediums
laboratori
particular
laboratori
littl
molecular
test
experi
limit
assay
includ
singl
test
format
requir
dedic
processor
sampl
h
multipl
processor
unit
would
need
larger
volum
laboratori
addit
instrument
would
increas
cost
lab
compar
use
instrument
run
multipl
test
time
respons
emerg
pandem
influenza
april
secretari
depart
health
human
servic
dhh
determin
public
health
emerg
affect
signific
potenti
affect
nation
secur
involv
specifi
biolog
agent
specifi
diseas
condit
may
attribut
agent
agent
basi
determin
secretari
dhh
declar
emerg
justifi
eua
ivd
devic
design
detect
influenza
viru
respons
may
cdc
receiv
eua
molecularbas
ivd
devic
detect
influenza
viru
manuscript
prepar
date
march
eua
grant
sever
modif
initi
cdc
test
addit
molecularbas
test
dfa
reagent
diagnost
hybrid
eua
inform
found
fda
websit
http
specif
test
list
tabl
test
author
march
major
test
use
realtim
rtpcr
n
perform
close
system
use
genexpert
dx
cepheid
tabl
use
genestat
system
dxna
tabl
simplexa
influenza
test
tabl
focu
diagnost
use
new
rapid
realtim
cycler
integr
cycler
medic
diagnost
cycler
small
footprint
cm
per
side
weight
approxim
kg
cycler
process
sampl
per
run
provid
result
min
diatherix
laboratori
influenza
test
use
qiagen
luminex
liquichip
qiagen
tabl
tessarray
resequenc
influenza
microarray
detect
panel
tessara
use
affymetrix
genechip
microarray
detect
system
affymetrix
tabl
current
littl
publish
data
perform
test
beyond
report
packag
insert
eua
test
list
tabl
rescind
june
juli
test
receiv
fda
approv
use
ivd
devic
diagnosi
pandem
influenza
first
test
approv
new
optim
cdc
assay
avail
cdcqualifi
laboratori
second
test
focu
diagnost
simplexa
influenza
perform
use
integr
cycler
use
fdaapprovedclear
naat
contrast
laboratorydevelop
test
substanti
benefit
laboratori
approv
test
undergon
extens
analyt
clinic
valid
cours
fda
evalu
therefor
perform
paramet
well
character
fda
monitor
postapprov
perform
laboratori
expertis
resourc
perform
extens
inhous
valid
studi
laboratorydevelop
test
recommend
clinic
laboratori
standard
institut
andor
requir
state
regulatori
agenc
colleg
american
pathologist
review
cost
perform
comprehens
laboratori
valid
laboratorydevelop
test
highli
variabl
depend
numer
factor
type
assay
eg
qualit
quantit
number
analyt
includ
test
eg
singleplex
multiplex
type
number
clinic
sampl
indic
test
eg
diagnosi
prognosi
monitor
technic
time
perform
studi
feder
state
regulatori
requir
laboratori
develop
valid
laboratorydevelop
test
cost
averag
per
analyt
fdaapprovedclear
naat
requir
laboratori
verif
perform
characterist
smaller
clinic
sampl
correl
studi
compar
laboratorydevelop
test
tabl
therebi
save
laboratori
consider
cost
technic
time
regulatori
requir
ongo
qualiti
assur
monitor
also
fewer
fdaapprovedclear
naat
laboratorydevelop
test
addit
regulatori
reason
health
care
institut
allow
use
fdaapprovedclear
naat
clinic
relev
assay
establish
use
fdaapprovedclear
naat
higher
chanc
reimburs
feder
privat
insur
payor
howev
fda
approvalclear
guarante
test
reimburs
reimburs
actual
amount
reimburs
vari
state
state
payor
final
simpletous
fulli
autom
molecular
platform
genexpert
genestat
incorpor
step
test
process
singl
test
cartridg
randomaccess
samplein
resultout
report
enabl
laboratori
size
perform
rapid
accur
sensit
molecular
diagnost
test
import
limit
current
fdaapprovedclear
naat
lack
test
detect
nonvir
target
particular
naat
need
detect
atyp
pneumonia
pathogen
howev
cost
clinic
trial
ivd
devic
clearanc
sometim
quit
prohibit
million
includ
cost
develop
manufactur
ivd
devic
depend
complex
clinic
relev
test
requir
fda
approv
eg
number
trial
site
number
patient
enrol
clinic
indic
sought
need
longterm
patient
followup
associ
diagnost
procedur
biopsi
devic
evalu
predic
devic
comparison
legal
regulatori
compon
forth
manufactur
must
consid
potenti
number
test
purchas
difficulti
trial
lowpreval
pathogen
commit
financ
resourc
bring
test
approv
process
factor
continu
limit
scope
fdaapprovedclear
naat
approv
process
modifi
encourag
submiss
naat
lowpreval
target
current
format
naat
requir
laboratori
choos
realtim
easier
perform
rapid
assay
limit
target
gener
highli
multiplex
test
requir
handson
time
technic
step
time
result
report
naat
limit
target
would
requir
laboratori
run
multipl
test
broader
rang
target
detect
indic
multipl
test
would
increas
requir
technic
time
cost
per
patient
diagnosi
convers
use
multipl
lower
multiplex
test
allow
select
appropri
panel
relat
age
patient
clinic
statu
underli
diseas
state
immun
compet
suspect
viru
es
current
develop
modifi
faster
version
highli
multiplex
assay
design
reduc
technic
handson
time
time
result
fdaapprovedclear
realtim
naat
allow
user
see
evalu
actual
amplif
curv
inabl
see
curv
make
difficult
troubleshoot
problem
occur
although
user
abl
alter
cutoff
valu
establish
fda
trial
access
part
raw
data
desir
one
caveat
qualit
naat
distinguish
live
dead
organ
therefor
depend
time
nucleic
acid
clearanc
limit
monitor
respons
therapi
addit
multipl
viral
infect
determin
relev
viru
present
sampl
difficult
residu
viru
detect
may
previou
infect
may
contribut
current
ill
develop
quantit
assay
evid
declin
viral
load
may
clarifi
resolv
issu
final
issu
relat
bill
reimburs
substanti
lack
specif
current
procedur
terminolog
cpt
code
individu
target
requir
laboratori
bill
multipl
target
use
gener
amplifi
probe
cpt
code
although
appropri
bill
target
present
multiplex
assay
use
cpt
code
multipl
time
singl
test
problemat
exampl
mani
laboratori
hospit
bill
system
recogn
multipl
similar
cpt
singl
test
drop
cpt
code
charg
insur
payor
cover
charg
first
cpt
code
also
limit
mani
time
per
day
similar
cpt
code
bill
result
reimburs
highli
multiplex
assay
could
limit
charg
therebi
significantli
increas
cost
laboratori
decreas
test
profit
circumst
pressur
reduc
medic
cost
mani
administr
approv
implement
test
reimburs
question
laboratori
need
analytespecif
cpt
code
payor
reimburs
medic
relev
naat
north
island
jewish
health
system
nslijh
infecti
diseas
molecular
diagnost
laboratori
open
year
ago
perform
test
human
immunodefici
viru
type
viral
load
amtd
chlamydia
trachomatisneisseria
gonorrhoea
naat
total
test
volum
test
per
year
today
laboratori
perform
naat
differ
pathogen
includ
bacteri
mycobacteri
fungal
parasit
viral
target
volum
test
per
year
space
tripl
size
molecular
diagnost
infecti
diseas
along
molecular
patholog
fastest
grow
laboratori
depart
nslijh
addit
best
exemplifi
anthrax
bioterror
event
influenza
pandem
laboratori
must
abl
respond
immedi
rapidli
expand
test
capabl
includ
sensit
specif
molecular
diagnost
onset
queen
new
york
area
influenza
outbreak
nslijh
laboratori
respiratori
viru
test
volum
increas
baselin
test
per
day
test
per
day
within
day
clear
first
week
outbreak
laboratori
urgent
need
switch
influenza
test
molecular
method
obtain
suffici
diagnost
sensit
subtyp
influenza
strain
fortun
fdaapprov
test
luminex
xtag
rvp
test
avail
met
diagnost
requir
laboratori
must
continu
plan
futur
pandem
outbreak
biothreat
event
therefor
laboratori
constantli
pressur
expand
test
meet
demand
clinic
staff
divers
patient
popul
laboratori
must
provid
clinic
relev
highqual
costeffect
naat
prefer
fda
approvedclear
move
forward
request
fda
work
close
organ
infecti
diseas
societi
america
american
societi
microbiolog
laboratori
director
ivd
devic
manufactur
goal
met
laborintens
complex
method
platform
yesterday
evolv
simpler
user
friendli
version
applic
health
care
set
encourag
fda
allow
submiss
process
evolv
similar
manner
longer
old
gold
standard
cultur
applic
new
way
evalu
test
must
consid
accur
perform
characterist
determin
costeffect
manner
latter
especi
true
lowvolum
highli
relev
assay
quantit
naat
transplant
monitor
reason
clear
regulatori
environ
ivd
devic
manufactur
succeed
bring
naat
approv
process
